

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 16, 2014**

**CYTORI THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**

**001-34375**

**33-0827593**

(State or other jurisdiction of incorporation)

(Commission File  
Number)

(I.R.S. Employer Identification No.)

**3020 Callan Road, San Diego, California 92121**  
(Address of principal executive offices) (Zip Code)

**(858) 458-0900**  
(Registrant's telephone number, including area code)

**n/a**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On October 16, 2014, Mr. Lloyd H. Dean notified Cytori Therapeutics, Inc., a Delaware corporation (the “Company”), of his decision to resign from the Company’s Board of Directors, such resignation to be effective November 1, 2014. Mr. Dean’s decision to resign as a director did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Company issued a press release announcing the resignation of Mr. Dean, a copy of which is filed hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release October 20, 2014

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTORI THERAPEUTICS, INC.**

Date: October 20, 2014

By:           /s/ Tiago Girao            
Tiago Girao  
Chief Financial Officer

---

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated October 20, 2014



October 20, 2014

**Cytori Therapeutics, Inc. Announces Resignation of Lloyd H. Dean Effective November 1, 2014**

SAN DIEGO – The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that Lloyd H. Dean has tendered his resignation as a member of the Board, effective November 1, 2014. Mr. Dean has served as a director of the Company since 2010 and served as Chairman of the Company’s Board of Directors from April 2011 until June 2013.

Mr. Dean said it has been an honor to serve the Company and its shareholders, but given his significant imperatives as President and CEO of Dignity Health, in addition to his ongoing involvement in healthcare activities at the regional, state and national level, that he would not be able to serve out the remainder of his term.

“Lloyd has made invaluable and impactful contributions to the Board and to the Company during his five years on the Board. We are thankful for Lloyd’s leadership over the past five years as the Company has undergone significant strategic, operational, and financial transformations,” said Marc Hedrick, M.D., President and Chief Executive Officer of Cytori. “He brought fresh ideas grounded in his deep knowledge of the healthcare industry and the real-world dynamic between hospitals and medical technology companies. We wish him the best in his future endeavors.”

“I am proud of our accomplishments over the past five years as we have transformed Cytori and taken the lead in regenerative medicine,” said Mr. Dean. “I am sincerely grateful for the support I’ve received from the Board of Directors, our management team, and our stakeholders. I look forward to seeing the Company continue to grow and successfully execute on its long-term strategy. While I am transitioning as a member of the Board, I will remain a fan and shareholder of Cytori.”

**About Cytori Therapeutics, Inc.**

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® system product family. For more information visit [www.cytori.com](http://www.cytori.com).

SOURCE Cytori Therapeutics, Inc.

Tiago Girao, Chief Financial Officer, 1.858.458.0900

[ir@cytori.com](mailto:ir@cytori.com)

---

